LAMIVUDINE = 3TC oral

Prescription under medical supervision


Therapeutic action

– Antiretroviral, HIV-1 and HIV-2 nucleoside reverse transcriptase inhibitor

Indications

– HIV-1 or HIV-2 infection, in combination with other antiretroviral drugs

Forms and strengths

– 150 mg and 300 mg tablets
– 50 mg/5 ml oral solution

Dosage

– Child under 1 month: 2 mg/kg 2 times daily 
– Child from 1 month to 12 years: 4 mg/kg 2 times daily
– Adult: 300 mg once daily 

Weight

10 mg/ml oral sol.

150 mg tablet

300 mg tablet

5 to 9 kg

2.5 ml x 2

10 to 14 kg

5 ml x 2

15 to 19 kg

7 ml x 2

½ tab x 2

20 to 24 kg

9 ml x 2

½ tab x 2

25 to 29 kg

11 ml x 2

2 tab

1 tab

≥ 30 kg

2 tab

1 tab

Duration

– The duration of treatment depends on the efficacy and tolerance of lamivudine.

Contra-indications, adverse effects, precautions

– Administer with caution to patients with history of hepatic disorders.
– May cause: gastrointestinal disturbances (diarrhoea, nausea, vomiting, etc.) and possibly: haematological disorders, especially when combined with zidovudine (neutropenia, anaemia, thrombocytopenia), myopathy, hepatic or pancreatic disorders.
– Reduce dosage in patients with renal impairment.
– Pregnancy: no contra-indication

Remarks

– For prophylactic treatment to reduce mother-to-child HIV transmission, check national recommendations.
– Many fixed-dose combinations containing lamivudine are available.
 Storage: below 25 °C
Once opened, oral solution keeps for 30 days maximum.